Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa: Results from a U.S. National sample

References

• Bell BP, Damon IK, Jernigan DB, Kenyon TA, Nichol ST, O'Connor JP, Tappero JW. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014–2016 Ebola Epidemic. MMWR Suppl. 2016;65(3):4–11. doi:10.15585/mmwr.su6503a2. PMID:27389903.
   PubMedGoogle Scholar
• World Health Organization. Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/ Accessed December 4, 2017.
   Google Scholar
• De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320. doi:10.1016/S1473-3099(15)00486-7. PMID:26725450.
   PubMed Web of Science ®Google Scholar
• Widdowson MA, Schrag SJ, Carter RJ, Carr W, Legardy-Williams J, Gibson L, Lisk DR, Jalloh MI, Bash-Taqi DA, Kargbo SA, et al. Implementing an Ebola Vaccine Study – Sierra Leone. MMWR Suppl. 2016;65(3):98–106. doi:10.15585/mmwr.su6503a14. PMID:27387395.
   PubMedGoogle Scholar
• Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, Wu SP, Li JX, Hu YM, Guo Q, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389(10069):621–628. doi:10.1016/S0140-6736(16)32617-4. PMID:28017399.
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315(15):1610–1623. doi:10.1001/jama.2016.4218. PMID:27092831.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518. doi:10.1016/S0140-6736(16)32621-6. PMID:28017403.
   PubMed Web of Science ®Google Scholar
• Venkatraman N, Silman D, Folegatti PM, Hill AVS. Vaccines against Ebola virus. Vaccine. 2017. [Epub ahead of print]. doi:10.1016/j.vaccine.2017.07.054.
   Google Scholar
• Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017;17(12):1276–1284. doi:10.1016/S1473-3099(17)30541-8. PMID:29033032.
   PubMed Web of Science ®Google Scholar
• Chevalier MS, Chung W, Smith J, Weil LM, Hughes SM, Joyner SN, Hall E, Srinath D, Ritch J, Thathiah P, et al. Ebola virus disease cluster in the United States–Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1087–1088. PMID:25412069.
   PubMed Web of Science ®Google Scholar
• Yacisin K, Balter S, Fine A, Weiss D, Ackelsberg J, Prezant D, Wilson R, Starr D, Rakeman J, Raphael M, et al. Ebola virus disease in a humanitarian aid worker – New York City, October 2014. MMWR Morb Mortal Wkly Rep. 2015;64(12):321–323. PMID:25837242.
   PubMed Web of Science ®Google Scholar
• Towers S, Afzal S, Bernal G, Bliss N, Brown S, Espinoza B, Jackson J, Judson-Garcia J, Khan M, Lin M, et al. Mass Media and the Contagion of Fear: The Case of Ebola in America. PLoS One. 2015;10(6):e0129179. doi:10.1371/journal.pone.0129179. PMID:26067433.
   PubMed Web of Science ®Google Scholar
• James JJ, Fearbola. Disaster Med Public Health Prep. 2014;8(6):465–466. doi:10.1017/dmp.2014.155. PMID:25859687.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine. 2014;32(39):5065–5070. doi:10.1016/j.vaccine.2014.07.003. PMID:25045822.
   PubMed Web of Science ®Google Scholar
• Harapan H, Fajar JK, Sasmono RT, Kuch U. Dengue vaccine acceptance and willingness to pay. Hum Vaccin Immunother. 2017;13(4):786–790. doi:10.1080/21645515.2016.1259045. PMID:27905832.
   PubMed Web of Science ®Google Scholar
• Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ, Pickering LK, Orenstein WA. Policy making for vaccine use as a driver of vaccine innovation and development in the developed world. Vaccine. 2017;35(10):1380–1389. doi:10.1016/j.vaccine.2016.10.080. PMID:28253995.
   PubMed Web of Science ®Google Scholar
• Hadisoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl Trop Dis. 2013;7(9):e2427. doi:10.1371/journal.pntd.0002427. PMID:24069482.
   PubMed Web of Science ®Google Scholar
• Lee JS, Mogasale V, Lim JK, Carabali M, Sirivichayakul C, Anh DD, Lee KS, Thiem VD, Limkittikul K, Tho le H, et al. A Multi-country Study of the Household Willingness-to-Pay for Dengue Vaccines: Household Surveys in Vietnam, Thailand, and Colombia. PLoS Negl Trop Dis. 2015;9(6):e0003810. doi:10.1371/journal.pntd.0003810. PMID:26030922.
   PubMed Web of Science ®Google Scholar
• Godoi IP, Santos AS, Reis EA, Lemos LL, Brandão CM, Alvares J, Acurcio FA, Godman B, Guerra Júnior AA. Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(R)) in Brazil; Implications for Future Pricing Considerations. Front Pharmacol. 2017;8:41. doi:10.3389/fphar.2017.00041. PMID:28210223.
   PubMed Web of Science ®Google Scholar
• Hou Z, Jie C, Yue D, Fang H, Meng Q, Zhang Y. Determinants of willingness to pay for self-paid vaccines in China. Vaccine. 2014;32(35):4471–4477. doi:10.1016/j.vaccine.2014.06.047. PMID:24968160.
   PubMed Web of Science ®Google Scholar
• Prosser LA, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113(2):283–290. doi:10.1542/peds.113.2.283. PMID:14754939.
   PubMed Web of Science ®Google Scholar
• Johnston SS, Rousculp MD, Palmer LA, Chu BC, Mahadevia PJ, Nichol KL. Employees' willingness to pay to prevent influenza. Am J Manag Care. 2010;16(8):e205–214. PMID:20690787.
   PubMed Web of Science ®Google Scholar
• Shono A, Kondo M. Parents' preferences for seasonal influenza vaccine for their children in Japan. Vaccine. 2014;32(39):5071–5076. doi:10.1016/j.vaccine.2014.07.002. PMID:25063570.
   PubMed Web of Science ®Google Scholar
• Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010;28(7):1702–1708. doi:10.1016/j.vaccine.2009.12.024. PMID:20044060.
   PubMed Web of Science ®Google Scholar
• Kruiroongroj S, Chaikledkaew U, Thavorncharoensap M. Knowledge, acceptance, and willingness to pay for human papilloma virus (HPV) vaccination among female parents in Thailand. Asian Pac J Cancer Prev. 2014;15(13):5469–5474. doi:10.7314/APJCP.2014.15.13.5469. PMID:25041020.
   PubMedGoogle Scholar
• Alder S, Gustafsson S, Perinetti C, Mints M, Sundstrom K, Andersson S. Mothers' acceptance of human papillomavirus (HPV) vaccination for daughters in a country with a high prevalence of HPV. Oncol Rep. 2015;33(5):2521–2528. doi:10.3892/or.2015.3817. PMID:25738832.
   PubMed Web of Science ®Google Scholar
• Kim SY, Sagiraju HK, Russell LB, Sinha A. Willingness-To-Pay for Vaccines in Low- and Middle-Income Countries: A Systematic Review. Annals of Vaccines and Immunization. 2014;1(1):1001.
   Google Scholar
• Ughasoro MD, Esangbedo DO, Tagbo BN, Mejeha IC. Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria. PLoS Negl Trop Dis. 2015;9(6):e0003838. doi:10.1371/journal.pntd.0003838. PMID:26076007.
   PubMed Web of Science ®Google Scholar
• Huo X, Shi G, Li X, Lai X, Deng L, Xu F, Chen M, Wei Q, Samba T, Liang X. Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone. Vaccine. 2016;34(15):1767–72. PMID:26928073.
   PubMed Web of Science ®Google Scholar
• Esangbedo DO, Ughasoro MD, Tagbo BN, Olowu A, Anikene C, Iwegbulam CC. Health-Care Workers' Perspectives on Ebola Virus Vaccine: A Focus Group and In-Depth Interview Interventional Study. Am J Trop Med Hyg. 2016;95(3):654–62.
   PubMed Web of Science ®Google Scholar
• Lang J, Wood SC. Development of orphan vaccines: an industry perspective. Emerg Infect Dis. 1999;5(6):749–56.
   PubMed Web of Science ®Google Scholar
• Lammert SM, Rao SR, Jentes ES, Fairley JK, Erskine S, Walker AT, Hagmann SH, Sotir MJ, Ryan ET, LaRocque RC. Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet. J Travel Med. 2016;24(1).
   PubMed Web of Science ®Google Scholar
• Painter JE, DiClemente RJ, von Fricken ME. Interest in an Ebola vaccine among a U.S. national sample during the height of the 2014–2016 Ebola outbreak in West Africa. Vaccine. 2017;35(4):508–512.
   PubMed Web of Science ®Google Scholar
• MacDonald, NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161–4. PMID:25896383.
   PubMed Web of Science ®Google Scholar
• Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, Meltzer MI. Effects of vaccine program against pandemic influenza A (H1N1) virus, United States, 2009–2010. Emerg Infect Dis. 2013;19:439–48.
   PubMed Web of Science ®Google Scholar
• U.S. Centers for Disease Control and Prevention. A CDC Framework for Preventing Infectious Diseases: Sustaining the Essentials and Innovating for the Future. 2011. https://www.cdc.gov/oid/docs/id-framework.pdf Accessed December 4, 2017.
   Google Scholar